A rare, cardiac condition characterized by severely decreased cardiac output, hypoperfusion and end-organ dysfunction, in the presence of adequate intravascular volume. The clinical presentation is va...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Documentation on cardiogenic shock is limited due to its rarity, affecting only 1-5 in 10,000 people. The complexity of its clinical presentation and the lack of identified genetic factors contribute to the challenges in gathering comprehensive data. As a result, systematic clinical studies have been scarce, making it difficult to establish a robust understanding of the condition.
The clinical picture of cardiogenic shock includes several key features. Most commonly, patients exhibit abnormal left ventricular function (80-99%), hypotension (80-99%), and abnormal EKG (80-99%). Other notable symptoms include dyspnea (30-79%), reduced consciousness (30-79%), and oliguria. These symptoms can lead to serious complications such as myocardial infarction and cardiac arrest, highlighting the critical nature of timely diagnosis and intervention.
To navigate your care for cardiogenic shock, consider consulting a cardiologist with expertise in heart failure and shock management. They can provide tailored treatment options and monitor your condition closely. Additionally, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org may offer valuable information and support. Participating in clinical trials could also be an option; check the ClinicalTrials.gov database for opportunities related to your condition. Genetic counseling may be beneficial to understand any potential familial implications.
There are currently two orphan drugs in development for cardiogenic shock: Hemoximer (pyridoxalated hemoglobin polyoxyethylene) and Tilarginine acetate. Additionally, there are 110 active clinical trials investigating various aspects of this condition. For more information on these trials, you can visit ClinicalTrials.gov and search for 'cardiogenic shock'. This ongoing research represents hope for improved management and treatment options in the future.
Actionable guidance for navigating care for cardiogenic shock
To navigate your care for cardiogenic shock, consider consulting a cardiologist with expertise in heart failure and shock management. They can provide tailored treatment options and monitor your condition closely. Additionally, resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org may offer valuable information and support. Participating in clinical trials could also be an option; check the ClinicalTrials.gov database for opportunities related to your condition. Genetic counseling may be beneficial to understand any potential familial implications.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 3 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.